Review of cost-effectiveness of antithrombotic alternatives in patients with atrial fibrillation

Rev Assoc Med Bras (1992). 2021 Jul;67(7):1050-1055. doi: 10.1590/1806-9282.20210332.
No abstract available

MeSH terms

  • Anticoagulants / therapeutic use
  • Atrial Fibrillation* / drug therapy
  • Cost-Benefit Analysis
  • Fibrinolytic Agents / therapeutic use
  • Humans
  • Stroke* / drug therapy
  • Stroke* / prevention & control
  • Warfarin

Substances

  • Anticoagulants
  • Fibrinolytic Agents
  • Warfarin